Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Gilead Sciences, Inc. (GILD): A Pharmaceutical Growth Story You Can’t Afford To Miss

Page 1 of 2

Gilead Sciences, Inc. (NASDAQ:GILD) is the world’s largest maker of HIV drugs, but has taken on a number of new initiatives to enter other areas of treatment. Gilead’s stock rose almost 80% in 2012, the best increase in 17 years, primarily on the prospects of  its experimental hepatitis C drug, acquired in its $10.8 billion acquisition of Pharmasset. Gilead’s string of deals clearly indicates that the company’s strategy includes blood cancer treatments in addition to hepatitis C. The market for treatment of leukemia and other blood cancers is one of the fastest growing markets in the cancer space.  In this article, I will examine Gilead’s fourth quarter financials, which have just been announced, and look at the market growth prospects for hepatitis C and blood cancer treatments.

Gilead Sciences, Inc. (NASDAQ:GILD)Fourth Quarter Highlights

Gilead recently announced results for the fourth quarter and full year 2012. Total revenues for the fourth quarter of 2012 grew by 18% to $2.59 billion, from $2.20 billion for the same quarter of the previous year. Net income for the quarter was $762.5 million, or an EPS of $0.47 per diluted share compared to $665.1 million, or an EPS of $0.43 per diluted share year on year.

Non-GAAP net income for the quarter, excluding acquisition-related, restructuring, and stock-based compensation expenses, was $823.4 million, or an EPS of $0.50 per diluted share compared to $743.1 million, or an EPS of $0.49 per diluted share, in the same quarter of the previous year. All these numbers have been adjusted to reflect the two-for-one stock split that became effective on Jan. 25, 2013.

For the full year 2012, total revenue was $9.70 billion, up 16% compared to $8.39 billion for the full year 2011. Net income was $2.59 billion, or an EPS of $1.64 per diluted share, compared to $2.80 billion, or an EPS of $1.77 per diluted share for the previous year. Non-GAAP net income for 2012, which does not include acquisition-related, restructuring and stock-based compensation expenses, was $3.08 billion, or $1.95 per diluted share, compared to $3.04 billion, or $1.93 per diluted share for the previous year.

As of Dec. 31, 2012, Gilead had $2.58 billion in cash, cash equivalents, and marketable securities against $9.96 billion as of Dec. 31, 2011. The decrease was caused by the acquisition of Pharmasset in the first quarter of 2012.  The company generated $3.19 billion in cash flow from operations in the full year 2012 and $705.7 million in the fourth quarter.

Phase 3 Studies – Sofosbuvir

Gilead reported that two phase 3 studies evaluating its hepatitis C therapy sofosbuvir had both met their primary endpoints and the data from the trials would support its regulatory filing for sofosbuvir. The company hopes to file for sofosbuvir’s approval with the FDA later this year. If it is approved, the drug, which Gilead acquired as part of its acquisition of Pharmasset, would be the first purely oral treatment for hepatitis C.

Analysts have estimated that the market for the disease could grow substantially in coming years, with a potential of $20 billion in revenue. Dr. Norbert Bischofberger, Gilead’s chief science officer and executive vice president of research and development, commented “These data support the favorable clinical profile of sofosbuvir as the backbone of a potent, safe, and well-tolerated treatment regimen that is effective across a broad range of HCV patient genotypes. The sofosbuvir regimens in these trials allowed us to shorten the duration of effective hepatitis C therapy to just 12 weeks for treatment-naive patients with genotypes 1 through 6.”  The hepatitis C treatment may generate as much as $3.8 billion in sales by 2020, according to Credit Suisse Group which would make it one of the company’s biggest products

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!